Skip to Content

Tazicef Side Effects

Generic Name: ceftazidime

Note: This document contains side effect information about ceftazidime. Some of the dosage forms listed on this page may not apply to the brand name Tazicef.

For the Consumer

Applies to ceftazidime: injection powder for solution

Along with its needed effects, ceftazidime (the active ingredient contained in Tazicef) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ceftazidime:

Less Common

  • Abdominal or stomach cramps or tenderness
  • bloating
  • bluish color
  • changes in skin color
  • diarrhea, watery and severe, which may also be bloody
  • fever
  • increased thirst
  • itching of the vagina or genital area
  • nausea or vomiting
  • pain
  • pain during sexual intercourse
  • swelling at the site of injection
  • swelling of the foot or leg
  • tenderness
  • thick, white vaginal discharge with no odor or with a mild odor
  • unusual tiredness or weakness
  • unusual weight loss
  • white patches in the mouth or throat or on the tongue
  • white patches with diaper rash


  • Back, leg, or stomach pains
  • bleeding gums
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • chills
  • cough
  • dark urine
  • difficulty with breathing
  • difficulty with swallowing
  • dizziness
  • fast heartbeat
  • general body swelling
  • headache
  • hives
  • itching
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • loss of appetite
  • nosebleeds
  • pale skin
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • shortness of breath
  • skin rash
  • sore throat
  • tightness in the chest
  • wheezing
  • yellowing of the eyes or skin

Incidence Not Known

  • Agitation
  • bloody or cloudy urine
  • blurred vision
  • change in consciousness
  • chest pain
  • clay-colored stools
  • confusion
  • coughing up blood
  • decreased frequency or amount of urine
  • diarrhea
  • difficult or painful urination
  • drowsiness
  • hallucinations
  • increased blood pressure
  • increased menstrual flow or vaginal bleeding
  • increased thirst
  • irritability
  • loss of consciousness
  • lower back or side pain
  • muscle twitching or jerking
  • nosebleeds
  • paralysis
  • prolonged bleeding from cuts
  • red or black, tarry stools
  • red or dark brown urine
  • rhythmic movement of the muscles
  • seizures
  • sores, ulcers, or white spots on the lips or in the mouth
  • stiff neck
  • sudden decrease in the amount of urine
  • swelling of the face, fingers, or lower legs
  • swollen or painful glands
  • troubled breathing
  • unpleasant breath odor
  • unusual bleeding or bruising
  • vomiting of blood
  • watery or bloody diarrhea
  • weight gain

Some side effects of ceftazidime may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

  • Red streaks on the skin
  • swelling, tenderness, or pain at the injection site

For Healthcare Professionals

Applies to ceftazidime: injectable powder for injection, intravenous powder for injection, intravenous solution


Discontinuation of ceftazidime (the active ingredient contained in Tazicef) may be necessary in severe, prolonged cases of diarrhea. Pseudomembranous colitis has been reported and should be considered if the patient does not respond to discontinuation of ceftazidime.[Ref]

Gastrointestinal side effects reported in less than 2% of patients have included diarrhea, nausea, vomiting, abdominal pain, and pseudomembranous colitis. Oral candidiasis has been reported in less than 1% of patients. Clostridium difficile associated diarrhea has also been reported.[Ref]


Mild hypersensitivity reactions, such as rash, pruritus, and fever, have been reported and may necessitate discontinuation of ceftazidime (the active ingredient contained in Tazicef) A case of asthma induced by occupational exposure to ceftazidime has been reported.

A case of occupational contact dermatitis due to cephalosporin allergy has been reported in a nurse who prepared cephalosporin solutions for administration to patients. The dermatitis resolved after the nurse stopped preparing the solutions.

A patient with sensitization to aztreonam showed cross-reactivity to ceftazidime. Ceftazidime and aztreonam contain the same side chain, which may explain the cross-sensitivity.[Ref]

Hypersensitivity reactions including rash, pruritus, and fever have been reported (2%). Cross reactions may occur in penicillin-allergic or aztreonam-allergic patients. Rarely, angioedema and anaphylactic reactions have occurred. Allergic reactions including cardiopulmonary arrest have been reported during postmarketing experience. Cephalosporin class antibiotics have been associated with Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis.[Ref]


Although increases in serum creatinine do not necessarily indicate renal toxicity, urinary alanine aminopeptidase (AAP) has been found to be significantly increased in some patients and may indicate renal tubular cell damage.[Ref]

Renal side effects have included transient increases in serum creatinine and BUN. Renal impairment has been reported during postmarketing experience. Cephalosporins as a class have been associated with renal dysfunction and toxic nephropathy.[Ref]

Nervous system

Ceftazidime-induced encephalopathy has been reported in an 80-year-old man with underlying renal dysfunction. This patient became incoherent and tremulous and had severe myoclonic jerking in all extremities. Therapy was discontinued and symptoms abated, but reappeared on rechallenge with a smaller dose. Symptoms again resolved with discontinuation of ceftazidime (the active ingredient contained in Tazicef) therapy. Several other cases of ceftazidime-induced encephalopathy, and hallucinations have been reported. In most cases the patients had underlying renal dysfunction. Symptoms were similar and resolved with dose reduction or drug discontinuation.

Neurologic reactions may be more likely to occur in patients with underlying renal dysfunction. Close monitoring of neurologic status is recommended.[Ref]

Nervous system side effects reported in less than 1% of patients have included headache, dizziness, paresthesia, and seizures. Encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have occurred in patients with renal dysfunction who received unadjusted doses of ceftazidime.[Ref]


Dermatologic side effects have included pemphigus erythematosus and urticaria.[Ref]


Local side effects have included phlebitis and inflammation at the injection site.[Ref]


Other transient hematologic effects, such as thrombocytopenia, thrombocytosis, and leukopenia, have been observed less frequently.[Ref]

Hematologic side effects have included transient eosinophilia, positive Coombs test without hemolysis, thrombocytosis, leukopenia, neutropenia, agranulocytosis, thrombocytopenia, and lymphocytosis. Cephalosporins as a class have been associated with aplastic anemia, hemolytic anemia, prolonged prothrombin time, hemorrhage, neutropenia, pancytopenia, and agranulocytosis.[Ref]


Hepatic side effects have included transient increases in AST, ALT, GGT, and alkaline phosphatase. These elevations generally resolve after discontinuation of therapy. Hyperbilirubinemia and jaundice have been reported during postmarketing experience. Cephalosporins as a class have been associated with hepatic dysfunction, including cholestasis.[Ref]


Genitourinary side effects have included vaginitis and candidiasis. Cephalosporins as a class have been associated with false-positive tests for urine glucose.[Ref]


Other side effects have included superinfection.[Ref]


1. Warns H, Lode H, Harnoss CM, et al "Multiple dose pharmacokinetics and therapeutic results with ceftazidime." J Antimicrob Chemother 12 (1983): 235-40

2. Ljungberg B, Nilsson-Ehle I "Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males." Eur J Clin Pharmacol 34 (1988): 179-86

3. Ljungberg B, Nilsson-Ehle I "Influence of age on the pharmacokinetics of ceftazidime in acutely ill, adult patients." Eur J Clin Pharmacol 34 (1988): 173-8

4. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH "Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia." Int J Antimicrob Agents 17 (2001): 497-504

5. "Product Information. Fortaz (ceftazidime)." Glaxo Wellcome, Research Triangle Park, NC.

6. Harding SM, Monro AJ, Thornton JE, et al "The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers." J Antimicrob Chemother 8 (1981): 263-72

7. Gentry LO "Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime." Pharmacotherapy 5 (1985): 254-67

8. Chierakul W, Anunnatsiri S, Short JM, et al. "Two Randomized Controlled Trials of Ceftazidime Alone versus Ceftazidime in Combination with Trimethoprim-Sulfamethoxazole for the Treatment of Severe Melioidosis." Clin Infect Dis 41 (2005): 1105-13

9. Kelkar PS, Li JT "Cephalosporin allergy." N Engl J Med 345 (2001): 804-9

10. Verhagen C, De Oauw BE, Williams KJ, Du Bois W "Ceftazidime sodium carbonate versus ceftazidime arginine as empirical monotherapy in febrile neutropenic patients." Eur J Clin Microbiol Infect Dis 7 (1988): 178-82

11. Pimiento AP, Martinez MG, Mena AM, Gonzalez AT, Arranz SD, Mosquera MR "Aztreonam and ceftazidime: evidence of in vivo cross-allergenicity." Allergy 53 (1998): 624-5

12. Filipe P, Almeida RSLS, Rodrigo FG "Occupational allergic contact dermatitis from cephalosporins." Contact Dermatitis 34 (1996): 226

13. Rodjer S, Alestig K, Bergmark J, et al "Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects." J Antimicrob Chemother 20 (1987): 109-16

14. Pizzo PA, Hathorn JW, Hiemenz J, et al "A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia." N Engl J Med 315 (1986): 552-8

15. Hillsley RE, Massey EW "Truncal asterixis associated with ceftazidime, a third-generation cephalosporin." Neurology 41 (1991): 2008

16. Slaker RA, Danielson B "Neurotoxicity associated with ceftazidime therapy in geriatric patients with renal dysfunction." Pharmacotherapy 11 (1991): 351-2

17. Klion AD, Kallsen J, Cowl CT, Nauseef WM "Ceftazidime-related nonconvulsive status epilepticus." Arch Intern Med 154 (1994): 586-9

18. Al-Zahawi MF, Sprott MS, Hendrick DJ "Hallucinations in association with ceftazidime." Br Med J 297 (1988): 858

19. Chow KM, Szeto CC, Hui AC, Wong TY, Li PK "Retrospective review of neurotoxicity induced by cefepime and ceftazidime." Pharmacotherapy 23 (2003): 369-73

20. Douglas MA, Quandt CM, Stanley DA "Ceftazidime-induced encephalopathy in a patient with renal impairment." Arch Neurol 45 (1988): 936-7

21. Chan S, Turner MR, Young L, Gregory R "Cephalosporin-induced myoclonus." Neurology 66 (2006): E20

22. Jackson GD, Berkovic SF "Ceftazidime encephalopathy: absence status and toxic hallucinations." J Neurol Neurosurg Psychiatry 55 (1992): 333-4

23. Pellicano R, Iannantuono M, Lomuto M "Pemphigus erythematosus induced by ceftazidime." Int J Dermatol 32 (1993): 675-6

24. Sommers DK, Walters L, Van Wyk M, et al "Pharmacokinetics of ceftazidime in male and female volunteers." Antimicrob Agents Chemother 23 (1983): 892-6

25. Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984): 325-30

26. Hui CH, Chan LC "Agranulocytosis associated with cephalosporin." BMJ 307 (1993): 484

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.